Abstract
Therapy with tyrosine kinase inhibitors (TKIs) is sufficient to prevent the progression to advanced chronic myeloid leukemia (CML) and inhibit recurrence. This has revolutionized the management of CML; but to maintain such “operational cure,” the Imatinib Mesylate (IM) is required indefinitely, incurring considerable cost and side effects due to the therapy.1
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
